Vivodyne, a startup spun out of the University of Pennsylvania, claims the AI drug discovery field is hampered by a lack of high-quality human biological data. The company has developed modular robotic labs called HIVE to generate this data by testing on 20 types of human tissue with high predictive accuracy for toxicity and drug efficacy. Vivodyne aims to provide the causal data needed to train more effective AI models, addressing a critical gap that leads to high failure rates in clinical trials. AI
IMPACT Vivodyne's approach could accelerate AI's impact on drug discovery by providing essential causal data, potentially reducing the high failure rate of drugs in clinical trials.
RANK_REASON Startup announces a novel infrastructure/product for AI development in a critical industry.
Read on Mastodon — mastodon.social →
- Cancer
- Robot Villas
- TechCrunch
- AlphaFold
- Andrei Georgescu
- Anthropic
- Dario Amodei
- Demis Hassabis
- Google DeepMind
- Isomorphic Labs
- Khosla Ventures
- OpenAI
- Sam Altman
- San Francisco
- University of Pennsylvania
- Vivodyne
AI-generated summary · Google Gemini · from 3 sources. How we write summaries →
